Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002
Allist Pharmaceuticals (SHA: 688578) announced that it has signed a strategic collaboration agreement with ArriVent...
NASDAQ: AVBP
Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...
Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...